CTI Life Sciences Ltd
Lakeside House
1 Furzeground Way
Stockley Park East
Uxbridge
UB11 1BD

By email
[redacted]
Level 1A, City Tower
Piccadilly Plaza
Manchester
M1 4BT

1st November, 2013

Dear [redacted],

Re: Pixantrone technology assessment - ID414

CTI Life sciences Ltd would like to thank NICE for allowing us to submit a revised PAS scheme for Pixantrone during the current assessment process.

We hope that the revised PAS and submission will address the uncertainties and concerns raised by the committee during the consultation process to date. In a separate letter and within the PAS template we have also tried to clarify the issues debated around PFS and OS which are discussed in the second ACD.

Following positive NICE guidance for Pixantrone, the PAS will be applied to all current and future Pixantrone indications and will be an important consideration in addressing the concerns of the NHS regarding affordability.

In case clarification is required on any aspect of our submission, please do not hesitate to contact me.

Yours sincerely,

[redacted]